Go to the profile of Symphogen

Symphogen

 

About Symphogen

Symphogen’s strategic priority is to commercialize our powerful research, preclinical and early development platform with the aim of establishing Symphogen as a preferred partner for the discovery and development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies. We will fully utilize the strengths of our technology platform and productive research engine, that have already successfully delivered high quality antibodies with unique functional properties and efficiently brought them to the clinic. Our heritage of identifying and developing combination therapies positions us at the core of future cancer treatments.

Therapeutic Areas

Oncology

Technologies

Other

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

September 2019